RESUMO
BACKGROUND: Radiotherapy, as a method of treatment of cervical and uterine cancers, may induce severe late-onset vaginal side effects. Unfortunately, little evidence on the management of adverse effects has been presented. This study aimed to evaluate the available interventions which reduce symptoms of vaginitis and vaginal atrophy by improving dyspareunia, mucosal inflammation, vaginal pH and vaginal dryness in women who have undergone brachytherapy or radiotherapy due to uterine or cervical malignancies. MATERIALS AND METHODS: A comprehensive literature search was performed following PRISMA guidelines. The systematic search was conducted using electronic databases, namely Scopus, Web of Science and PubMed, between October and November 2020 to identify randomized controlled trials (RCT) and, prospective randomized studies (PRS). RESULTS: The analyzed population consists of 376 patients with uterine or cervical cancer, treated with hyaluronic acid, vitamin A, vitamin E, alpha-tocopherol acetate and dienestrol. Intervention with HA along with vitamin A and vitamin E revealed advantage in endpoints such as reduced dyspareunia, vaginal mucosal inflammation, vaginal dryness, bleeding, fibrosis and cellular atypia. Administration of alpha-tocopherol acetate reduced vaginal mucosal inflammation and improved vaginal acanthosis, whereas dienestrol resulted in reduced dyspareunia, vaginal caliber and bleeding. CONCLUSIONS: Vaginal suppositories were found to be clinically effective at the management of late-onset vulvovaginal side effects after radiotherapy.
Assuntos
Braquiterapia , Dispareunia , Doenças Vaginais , Vaginite , Atrofia , Braquiterapia/efeitos adversos , Feminino , Humanos , Doenças Vaginais/etiologia , Doenças Vaginais/prevenção & controle , Vaginite/tratamento farmacológico , Vaginite/prevenção & controleRESUMO
BACKGROUND: The prevalence of North Korean female defectors is increasing in South Korea. Women who leave North Korea are exposed to sexual harassments, abuse, and other threats to their survival, which can have a devastating effect on their health. AIMS: In this study, a mobile video intervention program about selected aspects of women`s health was developed specifically for North Korean female defectors; its impact on behavioral change was evaluated. METHODS: A one group pre/posttest design was used with 61 female defectors who participated in the mobile video intervention. The program consisted of eight sessions focusing on the prevention and management of vaginitis and cervical cancer. RESULTS: The study results showed that knowledge and behavioral confidence on vaginitis and cervical cancer increased significantly among the participants following the intervention. CONCLUSIONS: This mobile video intervention program was effective in improving specific health knowledge and behavioral confidence of the participants. The program can be used to improve women`s health in this population.
Assuntos
Emigrantes e Imigrantes/educação , Neoplasias do Colo do Útero/prevenção & controle , Vaginite/prevenção & controle , Saúde da Mulher , Adulto , República Democrática Popular da Coreia , Feminino , Humanos , República da Coreia , Neoplasias do Colo do Útero/terapia , Vaginite/terapia , Adulto JovemRESUMO
We performed a prospective cohort parallel observational study on the use of Lactobacillus plantarum P 17630 in the prevention of vaginal infections. Eligible were women with a diagnosis of bacterial vaginosis (<15 days) and documented history of recurrent vaginal infections; and/or cystitis (<15 days); and/or treatment with antibiotics for bacterial respiratory tract infections during the week before the study entry. Study subjects were prescribed Lactobacillus plantarum P 17630 > 100.000.000 UFC one vaginal capsule per day for 6 days, then a capsule per week for 16 weeks. Eligible subjects were enrolled in two parallel cohorts: 85 women using (group A) and 39 not using (group B) Lactobacillus plantarum P 17630. The risk of recurrent infection within 4 months from the study entry, was higher among untreated women: multivariate OR 2.6 (95%CI 0.7-9.4). The modification of presence/intensity or symptoms was significant in both the study groups (p < .001). Impact statement What is already known on this subject? The Lactobacillus plantarum P 17630 has been shown to be active in the treatment of bacterial vaginosis and vaginal candidiasis. No data are available on its efficacy in the prevention of recurrent vaginal or urological infection or as a prevention strategy during systemic treatment with antibiotics. What do the results of this study add? This observational study suggests that Lactobacillus plantarum given for 4 months may lower the risk of recurrent infection in women with recurrent vaginal or genitourinary infection or after antibiotic systemic treatment for bacterial respiratory tract infection. The finding, however, is not statistically significant, possibly due to the lower than expected rate of infection observed in our population and consequently the limited power of the study. What are the implications of these findings for clinical practice and/or further research? New studies are needed in order to evaluate in different populations the role of Lactobacillus plantarum in lowering the risk of recurrent infection in a high-risk populations.
Assuntos
Antibacterianos/efeitos adversos , Cistite/prevenção & controle , Lactobacillus plantarum , Probióticos/uso terapêutico , Vaginite/prevenção & controle , Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Infecções Respiratórias/tratamento farmacológico , Prevenção Secundária , Vaginite/induzido quimicamenteRESUMO
BACKGROUND: Hotel-based sex workers in Bangladesh have high rates of sexually transmissible infections (STIs), high client turnover and low condom use. Two monthly clinic-based strategies were compared: periodic presumptive treatment (PPT) and enhanced syndromic management (ESM) - one round of presumptive treatment followed by treatment based on assessment and laboratory tests. METHODS: A randomised controlled trial compared PPT and ESM by prevalence and incidence, behaviour, retention, cost and STI incidence and prevalence. Demographic, behavioural and clinical data were collected from women at two clinics in Dhaka. All women received presumptive treatment and were randomised to receive PPT or ESM at nine monthly visits. RESULTS: In total, 549 women (median age: <20 years) were enrolled. At baseline, the prevalence of chlamydia (Chlamydia trachomatis) and gonorrhoea (Neisseria gonorrhoeae) was 41% (ESM: 41%; PPT: 42%). After 9 months, chlamydia and gonorrhoea decreased to 7% overall, (ESM: 7.4%; PPT: 6.8%). At each visit, 98% of women receiving ESM met the therapy criteria and were treated. Retention was low (50%). Total costs were 50% lower per visit for each woman for PPT (ESM: $11.62 v. PPT: $5.80). The number of sex work sessions was reduced from 3.3 to 2.5 (P<0.001), but income did not change. Coercion was reduced but condom use at last sex did not change significantly. CONCLUSIONS: Monthly PPT and ESM were effective approaches for STI control. PPT offered a feasible, low-cost alternative to ESM. Educational aspects led to a reduction in coercion and fewer sessions. Implementation studies are needed to improve condom use and retention.
Assuntos
Antibacterianos/administração & dosagem , Azitromicina/administração & dosagem , Cefixima/administração & dosagem , Preservativos/estatística & dados numéricos , Países em Desenvolvimento , Metronidazol/administração & dosagem , Doenças Profissionais/prevenção & controle , Profissionais do Sexo , Infecções Sexualmente Transmissíveis/prevenção & controle , Local de Trabalho , Adolescente , Bangladesh , Candidíase Vulvovaginal/epidemiologia , Candidíase Vulvovaginal/prevenção & controle , Infecções por Chlamydia/epidemiologia , Infecções por Chlamydia/prevenção & controle , Chlamydia trachomatis , Terapia Combinada , Estudos Transversais , Quimioterapia Combinada , Feminino , Gonorreia/epidemiologia , Gonorreia/prevenção & controle , Educação em Saúde , Humanos , Incidência , Programas de Rastreamento , Doenças Profissionais/epidemiologia , Infecções Sexualmente Transmissíveis/epidemiologia , Vaginite por Trichomonas/epidemiologia , Vaginite por Trichomonas/prevenção & controle , Cervicite Uterina/epidemiologia , Cervicite Uterina/prevenção & controle , Revisão da Utilização de Recursos de Saúde , Vaginite/epidemiologia , Vaginite/prevenção & controle , Vaginose Bacteriana/epidemiologia , Vaginose Bacteriana/prevenção & controle , Adulto JovemRESUMO
Probiotics are derived from traditional fermented foods, from beneficial commensals or from the environment. They act through diverse mechanisms affecting the composition or function of the commensal microbiota and by altering host epithelial and immunological responses. Certain probiotic interventions have shown promise in selected clinical conditions where aberrant microbiota have been reported, such as atopic dermatitis, necrotising enterocolitis, pouchitis and possibly irritable bowel syndrome. However, no studies have been conducted that can causally link clinical improvements to probiotic-induced microbiota changes. Whether a disease-prone microbiota pattern can be remodelled to a more robust, resilient and disease-free state by probiotic administration remains a key unanswered question. Progress in this area will be facilitated by: optimising strain, dose and product formulations, including protective commensal species; matching these formulations with selectively responsive subpopulations; and identifying ways to manipulate diet to modify bacterial profiles and metabolism.
Assuntos
Nível de Saúde , Síndrome do Intestino Irritável/tratamento farmacológico , Probióticos/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Neoplasias Colorretais/prevenção & controle , Doença de Crohn/tratamento farmacológico , Infecção Hospitalar/prevenção & controle , Diarreia/tratamento farmacológico , Diarreia/microbiologia , Enterocolite Necrosante/prevenção & controle , Medicina Baseada em Evidências , Feminino , Humanos , Hipersensibilidade/prevenção & controle , Metanálise como Assunto , Vaginite/prevenção & controleRESUMO
Multiple intravaginal HIV prevention methods, including microbicide gels, barriers, and intravaginal rings, are in clinical development in Africa. Development of intravaginal HIV prevention products requires an understanding of sexual behavior, sexually transmitted infection (STI), and vaginitis prevalences, and sexual and vaginal practices in potential target populations. We assessed these factors in a cohort of Kenyan female sex workers (FSW). Women who reported exchanging sex for money/gifts at least three times in the past month and who were HIV uninfected were enrolled and followed for 6 months. STI prevalence and HIV incidence were analyzed by multivariate logistic regression analysis, controlling for demographic and behavioral factors. Thirty-seven percent (74/200) reported having had anal sex. Frequency of anal sex was higher with regular and casual partners than with primary partners. Women were less likely to use condoms for anal sex than for vaginal sex with regular or casual partners. Vaginal washing was universal (100%). HIV incidence was 5.6 per 100 person-years (95% CI 1.62, 11.67). HIV incidence was not associated with any demographic or risk behavior. The relatively high rate of anal sex and universal vaginal washing may complicate both safety and efficacy evaluation of intravaginal products and should be taken into account in trial design. This FSW population had significant HIV incidence and needs continued HIV prevention interventions.
Assuntos
Infecções por HIV/prevenção & controle , HIV/patogenicidade , Profissionais do Sexo/estatística & dados numéricos , Comportamento Sexual/estatística & dados numéricos , Vaginite/prevenção & controle , Adolescente , Adulto , Estudos de Coortes , Preservativos Femininos/estatística & dados numéricos , Feminino , Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , Humanos , Incidência , Quênia/epidemiologia , Modelos Logísticos , Pessoa de Meia-Idade , Razão de Chances , Parceiros Sexuais , População Urbana , Ducha Vaginal/métodos , Vaginite/diagnóstico , Vaginite/epidemiologia , Vaginite/microbiologia , Vaginite/virologia , Adulto JovemRESUMO
OBJECTIVE: To identify the risk factors of HIV vertical transmission in pregnant women. STUDY DESIGN: Observational cohort study. Between 2002 and 2003, 479 HIV-infected pregnant women in a PMTCT (prevention of the mother-to-child transmission) program were followed up with their infants at delivery, until 15 months with infant HIV testing. RESULTS: Of these 281 infants had a definitive HIV result by 15 months of age, and 31.7% of the infants become HIV infected. In univariate analysis the risk factor identified were presence of vaginal discharge, genital itchiness, genital ulcers, dysuria, abnormal breast and vaginal infections (Trichomonas, Bacteria vaginosis and Candida) in the mother at enrolment. In multivariate analysis vaginal infections risk ratio (RR) 1.72(1.03-2.88) and abnormal breast RR 4.36(2.89-6.58) were predictors of HIV vertical transmission. CONCLUSION: There is need to screen for vaginal infections (Trichomonas, Bacteria vaginosis and Candida) and examine pregnant women for mastitis to identify women at risk of HIV vertical transmission for prevention.
Assuntos
Infecções por HIV/transmissão , HIV , Transmissão Vertical de Doenças Infecciosas , Mastite/prevenção & controle , Complicações Infecciosas na Gravidez , Vaginite/prevenção & controle , Estudos de Coortes , Feminino , Infecções por HIV/complicações , Infecções por HIV/prevenção & controle , Humanos , Lactente , Recém-Nascido , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Mastite/etiologia , Área Carente de Assistência Médica , Gravidez , Desenvolvimento de Programas , Fatores de Risco , Vaginite/etiologia , ZimbábueAssuntos
Benzidamina/uso terapêutico , Proctite/tratamento farmacológico , Proctite/prevenção & controle , Neoplasias Uterinas/radioterapia , Neoplasias Vaginais/radioterapia , Vaginite/tratamento farmacológico , Vaginite/prevenção & controle , Adulto , Idoso , Benzidamina/administração & dosagem , Esquema de Medicação , Feminino , Humanos , Pessoa de Meia-Idade , Proctite/etiologia , Radioterapia/efeitos adversos , Resultado do Tratamento , Neoplasias do Colo do Útero/radioterapia , Vaginite/etiologiaRESUMO
Whether persistent human papillomavirus (HPV) IgG antibodies following natural infection are protective against subsequent infection is unknown. In a cohort of 508 college women followed for 3 y, persistent seropositivity was defined as the presence of type-specific HPV virus-like particle (VLP) antibodies at > or = 2 consecutive visits 1 y apart. Protection from incident infection with any HPV was conferred by persistent antibodies to HPV16 (p = 0.02), HPV31 (p < 0.001), HPV33 (p = 0.03), HPV35 (p = 0.002), HPV52 (p = 0.007), HPV45 (p = 0.003), and HPV53 (p = 0.01). The risk of incident infection with species-specific HPV types was also decreased in women with persistent antibodies to any HPV type in that group, suggesting that exposure to HPV with persistent development of antibody response can be protective, and may explain the decreased efficacy of HPV vaccine in women with prior exposure.
Assuntos
Alphapapillomavirus/imunologia , Anticorpos Antivirais/imunologia , Proteínas do Capsídeo/imunologia , Imunoglobulina G/imunologia , Proteínas Oncogênicas Virais/imunologia , Infecções por Papillomavirus/imunologia , Cervicite Uterina/prevenção & controle , Vaginite/prevenção & controle , Interferência Viral , Adolescente , Adulto , Alphapapillomavirus/classificação , Sondas de DNA de HPV , DNA Viral/análise , Feminino , Seguimentos , Humanos , Risco , Estudos Soroepidemiológicos , Comportamento Sexual , Parceiros Sexuais , Especificidade da Espécie , Cervicite Uterina/imunologia , Cervicite Uterina/virologia , Vaginite/imunologia , Vaginite/virologia , Latência Viral , Adulto JovemAssuntos
Cervicite Uterina , Vaginite , Feminino , Humanos , Programas de Rastreamento/métodos , Guias de Prática Clínica como Assunto , Gravidez , Fatores de Risco , Estados Unidos , Cervicite Uterina/diagnóstico , Cervicite Uterina/tratamento farmacológico , Cervicite Uterina/prevenção & controle , Vaginite/diagnóstico , Vaginite/tratamento farmacológico , Vaginite/prevenção & controleAssuntos
Anti-Inflamatórios/uso terapêutico , Benzidamina/uso terapêutico , Proctite , Radioterapia/efeitos adversos , Neoplasias Uterinas/radioterapia , Neoplasias Vaginais/diagnóstico por imagem , Vaginite , Adulto , Idoso , Anti-Inflamatórios/administração & dosagem , Benzidamina/administração & dosagem , Feminino , Humanos , Pessoa de Meia-Idade , Proctite/tratamento farmacológico , Proctite/etiologia , Proctite/prevenção & controle , Radiografia , Resultado do Tratamento , Vaginite/tratamento farmacológico , Vaginite/etiologia , Vaginite/prevenção & controleRESUMO
This study analyzes the phenotype of vaginal dendritic cells (VDCs), their antigenic presentation and activation of T-cell cytokine secretion, and their protective role in a rat model of Candida vaginitis. Histological observation demonstrated a significant accumulation of OX62(+) VDCs in the mucosal epithelium of Candida albicans-infected rats at the third round of infection. We identified two subsets of OX62(+) VDCs differing in the expression of CD4 molecule in both noninfected and Candida-infected rats. The OX62(+) CD4(+) subset of VDCs displayed a lymphoid cell-like morphology and expressed the T-cell antigen CD5, whereas the OX62(+) CD4(-) VDC subset exhibited a myeloid morphology and was CD5 negative. Candida infection resulted in VDC maturation with enhanced expression of CD80 and CD134L on both CD4(+) and CD4(-) VDC subsets at 2 and 6 weeks after Candida infection. CD5(-) CD4(-) CD86(-) CD80(-) CD134L(+) VDCs from infected, but not noninfected, rats spontaneously released large amounts of interleukin-12 (IL-12) and tumor necrosis factor alpha, whereas all VDC subsets released comparable levels of IL-10 and IL-2 cytokines. Furthermore, OX62(+) VDCs from infected rats primed naïve CD4(+) T-cell proliferation and release of cytokines, including gamma interferon, IL-2, IL-6, and IL-10, in response to staphylococcal enterotoxin B stimulation in vitro. Adoptive transfer of highly purified OX62(+) VDCs from infected rats induced a significant acceleration of fungal clearance compared with that in rats receiving naive VDCs, suggesting a protective role of VDCs in the anti-Candida mucosal immunity. Finally, VDC-mediated protection was associated with their ability to rapidly migrate to the vaginal mucosa and lymph nodes, as assessed by adoptive transfer of OX62(+) VDCs labeled with 5 (and 6-)-carboxyfluorescein diacetate succinimidyl ester.
Assuntos
Candida albicans/imunologia , Candidíase/imunologia , Candidíase/patologia , Células Dendríticas/imunologia , Vaginite/imunologia , Vaginite/patologia , Transferência Adotiva , Animais , Candidíase/prevenção & controle , Proliferação de Células , Células Cultivadas , Células Dendríticas/patologia , Células Dendríticas/transplante , Feminino , Imunidade nas Mucosas , Imunofenotipagem , Linfonodos/imunologia , Linfonodos/patologia , Ratos , Ratos Wistar , Vagina/imunologia , Vagina/patologia , Vaginite/prevenção & controleAssuntos
Terapia de Reposição de Estrogênios/efeitos adversos , Pós-Menopausa , Incontinência Urinária/etiologia , Infecções Urinárias/etiologia , Sistema Urogenital/efeitos dos fármacos , Androgênios/deficiência , Atrofia , Feminino , Humanos , Recidiva , Fatores de Risco , Incontinência Urinária/prevenção & controle , Infecções Urinárias/prevenção & controle , Vaginite/etiologia , Vaginite/prevenção & controleRESUMO
Practical results of screening cytological diagnosis of urogenital infections in pregnant women and mass pathomorphological investigations of newborn placentas performed by bureaus of pathology in Leningrad region and Cheboksary city are reviewed. Important place of the ascending bacterial infection in the structure of reproductive mortality is emphasized.
Assuntos
Aborto Espontâneo/prevenção & controle , Doenças Urogenitais Femininas/prevenção & controle , Programas Governamentais , Programas de Rastreamento , Patologia Clínica , Complicações Infecciosas na Gravidez/prevenção & controle , Aborto Espontâneo/patologia , Estudos Transversais , Feminino , Doenças Urogenitais Femininas/patologia , Morte Fetal/prevenção & controle , Humanos , Placenta/patologia , Doenças Placentárias/patologia , Doenças Placentárias/prevenção & controle , Gravidez , Complicações Infecciosas na Gravidez/patologia , Trimestres da Gravidez , Federação Russa , Vaginite/patologia , Vaginite/prevenção & controleRESUMO
The aim of this study was to test the hypothesis that polyvinylpyrrolidone (PVP) would increase the critical micelle concentration (CMC) of nonoxynol-9 (N-9), providing a reduction in its irritation potential, while maintaining essential spermicidal activity. Solid coprecipitates of N-9 with PVP were manufactured with the use of a modified lyophilization process. The irritation potential of N-9 was estimated by an in vitro assay, monitoring the extent of hemolysis of red blood cells. CMCs of N-9 were measured in the presence of various concentrations of PVP. A modified Sander-Cramer assay was implemented to measure the spermicidal activity of N-9 and the N-9/PVP coprecipitates. With the use of the lyophilization process and more suitable solvents, solid coprecipitates of N-9/PVP were manufactured with no residual organic solvents. The irritation potential of N-9 was reduced when in the presence of PVP-50% hemolysis values increased from 0.054 mM to more than 0.2mM. N-9 CMC values increased in the presence of PVP from 0.085 mM (0% PVP) to 0.110 mM (3.5% PVP) and 0.16 6mM (10% PVP). However, spermicidal activities ranged from 0.213 mM to 0.238 mM, N-9 remaining steady regardless of the amount of PVP. By use of N-9/PVP coprecipitates, the self-association properties and irritation potentials of N-9 were altered. This result suggests a process to produce a spermicidal product that reduces the detrimental implications to the vaginal epithelium while maintaining the essential spermicidal activity.
Assuntos
Nonoxinol/química , Povidona/química , Animais , Bioensaio , Precipitação Química , Cães , Eritrócitos/efeitos dos fármacos , Feminino , Hemólise/efeitos dos fármacos , Humanos , Irritantes/administração & dosagem , Irritantes/efeitos adversos , Irritantes/antagonistas & inibidores , Masculino , Micelas , Nonoxinol/administração & dosagem , Nonoxinol/efeitos adversos , Excipientes Farmacêuticos/química , Excipientes Farmacêuticos/uso terapêutico , Povidona/uso terapêutico , Espermicidas/administração & dosagem , Espermicidas/efeitos adversos , Espermicidas/química , Espermatozoides/metabolismo , Vaginite/etiologia , Vaginite/prevenção & controleRESUMO
The investigation has been concerned with the efficacy of Tantum Rosa (Angelini Francesco, Italy) in the prevention (21) and therapy (87) of early- and late-onset radiation injuries of the rectum and vagina in patients exposed to radiation for cervical, uterine or vaginal carcinoma. Rectal tenesmus and pain subsided following 3-4 administrations at early stages of radiation rectitis. Intestinal discomfort was avoided when Tantum Rosa was used for prophylaxis. Therapeutic effect was reported after 7-10 administrations for moderate radiation vaginitis. Therapy for pannicular epithelite lasted less than two weeks.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Neoplasias do Endométrio/radioterapia , Proctite/tratamento farmacológico , Proctite/prevenção & controle , Neoplasias Vaginais/radioterapia , Vaginite/tratamento farmacológico , Vaginite/prevenção & controle , Adulto , Idoso , Relação Dose-Resposta à Radiação , Feminino , Humanos , Pessoa de Meia-Idade , Proctite/etiologia , Radioterapia/efeitos adversos , Resultado do Tratamento , Vaginite/etiologiaRESUMO
Emerging from the stigma of once being referred to as "snake oil", excellent scientific and clinical evidence now exists to indicate that probiotics do indeed have a role to play in medicine. The proper definition of probiotics is important "Live microorganisms which when administered in adequate amounts confer a health benefit on the host", for several reasons. It rules out so-called probiotics that have no clinically proven, peer-reviewed data, and it states the need to have viable bacteria present, unlike these pseudo products which are often wrongly labeled, poorly manufactured, with low or no viability at time of use. Guidelines, prepared by the United Nations and World Health Organization are now available to guide physicians and consumers as to the types of strains with documented benefits. In urology, the most studied strains are Lactobacillus rhamnosus GR-1 and L. fermentum B-54 and RC-14. Their use daily in oral form, or once to three times weekly as a vaginal suppository, have been shown to reduce the urogenital pathogen load and the risk of urinary tract and vaginal infections. Organisms such as Oxalobacter formigenes, still in the R&D phase, offer great potential to reduce kidney stone formation via oxalate degradation in the intestine. Some studies using L. casei Shirota suggest a possible effect against bladder cancer, while studies using L. plantarum 299 show significantly reduced infection rates in patients undergoing major surgical procedures. In short, specific probiotic strains hold much promise for use in the urology setting.
Assuntos
Doenças Urogenitais Femininas/prevenção & controle , Probióticos , Feminino , Humanos , Lactobacillus , Oxalobacter formigenes , Complicações Pós-Operatórias/prevenção & controle , Prevenção Secundária , Infecções Urinárias/prevenção & controle , Vaginite/microbiologia , Vaginite/prevenção & controleRESUMO
OBJECTIVE: To examine the effects of oral estrogen/progestin on incontinence and related lower urinary tract conditions among female nursing home (NH) residents. DESIGN: Randomized placebo-controlled trial. SETTING: Five NHs. PARTICIPANTS: Thirty-two incontinent female residents of average age 88. MEASUREMENTS: Subjects were randomized to receive either oral estrogen (0.625 mg) combined with progesterone (2.5 mg) or placebo, daily for 6 months. Measures of incontinence severity, the clinical appearance of the vagina, vaginal and urethral cytology, and urine and vaginal cultures were made at baseline, 3 months, and 6 months. In addition to active drug or placebo, all subjects received regular toileting assistance (prompted voiding) by trained research aides during 3-day data-collection periods to compensate for mobility and cognitive impairments. RESULTS: At 3 and 6 months there were no significant differences between the groups in the severity of incontinence, the prevalence of bacteriuria, or the results of vaginal cultures. Several clinical findings associated with atrophic vaginitis improved more in the active than the placebo group and vaginal pH and vaginal and urethral cytology exhibited a partial estrogenic effect. CONCLUSIONS: Our results must be interpreted with caution because of the size and the select nature of our subject sample. Up to 6 months of oral estrogen had only a partial estrogenic effect on vaginal and urethral epithelium and no clinical effects in this patient population. We believe that future studies of estrogen for urinary incontinence in frail NH residents should utilize a topical preparation and consider targeting urinary tract infection as an additional outcome measure.